Fundamental challenges to the development of a preventive HIV vaccine

被引:10
|
作者
Rios, Adan [1 ,2 ]
机构
[1] Photolmmune Biotechnol Inc, Houston, TX 77046 USA
[2] McGovern Univ Texas Med Sch Houston, Houston, TX 77030 USA
关键词
BROADLY NEUTRALIZING ANTIBODIES; AFFINITY MATURATION; FOUNDER VIRUS; EVOLUTION; TRANSMISSION; INFECTION; IDENTIFICATION; ENVELOPE; DISEASE; DESIGN;
D O I
10.1016/j.coviro.2018.02.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
There is consensus that only a preventive vaccine can contain the HIV/AIDS pandemic. After 30 years still there is no preventive HIV vaccine. This article examines fundamental challenges to the development of a preventive HIV vaccine. They include the initially erroneous but powerful perception of the natural history of HIV disease, as an acute rather than a chronic illness even in the absence of therapy, the lack of appreciation of the quasispecies biology of HIV and the abandonment of principles of immunology theory caused by the allure of technological prowess. In addition two other important aspects are discussed: vaccines directed against transmitted/founder viruses (T/F) and the reconsideration of HIV inactivation as a viable means to obtain a preventive HIV vaccine using novel safe methods of inactivation not available during the early years of the pandemic.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 50 条
  • [31] Challenges in vaccine development
    Burnette, WN
    PERIODICUM BIOLOGORUM, 1998, 100 : 155 - 160
  • [32] Queering Development and the Emergence of Virtual Communities in Asia: Challenges and Opportunities for HIV Preventive Interventions
    Guadamuz, Thomas
    CULTURE HEALTH & SEXUALITY, 2009, 11 : 30 - 30
  • [33] HIV vaccine development
    Singh, M
    Jeang, KT
    Smith, SM
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 2064 - 2081
  • [34] …and in HIV vaccine development
    Karen Birmingham
    Nature Medicine, 1998, 4 (6) : 648 - 649
  • [35] HIV Vaccine-Challenges and Opportunities
    Xin MA
    Virologica Sinica, 2007, (06) : 486 - 492
  • [36] The challenges of an HIV vaccine enterprise - Response
    Klausner, RD
    Fauci, AS
    Corey, L
    Nabel, GJ
    Gayle, H
    Berkley, S
    Haynes, BF
    Baltimore, D
    Collins, C
    Douglas, RG
    Esparza, J
    Francis, DP
    Ganguly, NK
    Gerberding, JL
    Johnson, MI
    Kazatchkine, MD
    McMichael, AJ
    Makgoba, MW
    Pantaleo, G
    Piot, P
    Shao, YM
    Tramont, E
    Varmus, H
    Wasserheit, JN
    SCIENCE, 2004, 303 (5662) : 1296 - 1297
  • [37] Immune response to develop potential preventive HIV vaccine
    不详
    DRUG NEWS & PERSPECTIVES, 2000, 13 (02) : 114 - 115
  • [38] The complex challenges of HIV vaccine development require renewed and expanded global commitment
    Bekker, Linda-Gail
    Tatoud, Roger
    Dabis, Francois
    Feinberg, Mark
    Kaleebu, Pontiano
    Marovich, Mary
    Ndung'u, Thumbi
    Russell, Nina
    Johnson, Jeremiah
    Luba, Maureen
    Fauci, Anthony S.
    Morris, Lynn
    Pantaleo, Giuseppe
    Buchbinder, Susan
    Gray, Glenda
    Vekemans, Johan
    Kim, Jerome H.
    Levy, Yves
    Corey, Lawrence
    Shattock, Robin
    Makanga, Michael
    Williamson, Carolyn
    Dieffenbach, Carl
    Goodenow, Maureen M.
    Shao, Yiming
    Staprans, Silvija
    Warren, Mitchell
    Johnston, Margaret I.
    LANCET, 2020, 395 (10221): : 384 - 388
  • [39] Distinct advancements and challenges in HIV 1 vaccine development and cure-A review
    Dangeti, Sandeep Raja
    HIV & AIDS REVIEW, 2014, 13 (01): : 1 - 5
  • [40] Epidemiological considerations in planning HIV preventive vaccine trials
    Esparza, J
    Burke, D
    AIDS, 2001, 15 : S49 - S57